RxDoctor Payments Data

Anandita Arora, MD

Internal Medicine · Rome, GANPI 1154731925

Payments from drug & device makers

$5,394in general payments, 2019–2025

Across 352 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$918
  • Pfizer$576
  • GSK$472
  • Amgen$406
  • Novo Nordisk$364
  • Boehringer Ingelheim$363
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$5,394100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,394 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$135,029
Medicare patients
201
Services billed
5,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol105$124,412
EliquisApixaban59$67,122
JardianceEmpagliflozin43$64,861
MounjaroTirzepatide44$63,562
OzempicSemaglutide46$54,194
ProliaDenosumab26$44,062
JanuviaSitagliptin Phosphate21$31,103
GemtesaVibegron27$29,814
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$26,627
RybelsusSemaglutide13$25,028
KerendiaFinerenone20$15,258
TrulicityDulaglutide14$13,772
BelsomraSuvorexant12$12,903
Breo ElliptaFluticasone/Vilanterol22$11,531
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$10,893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$56$140,380140 claims
Novo NordiskOzempic, Rybelsus$364$79,22259 claims
Lilly USA, LLCMounjaro, Trulicity$280$77,33558 claims
PfizerEliquis$576$67,12259 claims
Boehringer IngelheimJardiance$363$64,86143 claims
AmgenProlia$406$44,06226 claims
MerckJanuvia, Belsomra$143$44,00633 claims
GSKTrelegy Ellipta, Breo Ellipta$472$38,15846 claims
Sumitomo Pharma America, Inc.Gemtesa$108$29,81427 claims
BayerKerendia$151$15,25820 claims
AbbVieSynthroid$918$2,32024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →